Laboratory of Alan Landay, PhD

The advent of successful antiretroviral therapy, or ART, for those with HIV infection has led to significant improvement in patient mortality and morbidity. However, even with the gains in quality of life  immune activation/inflammation persists and can result in the development of serious non-AIDS events in people infected with HIV. Our  laboratory group is interested in studying mechanisms that contribute to mucosal and systemic inflammation.

Our work

We have multiple ongoing research projects focused on understanding both the cause and the consequences of  immune pathogenesis and inflammation in HIV and chronic diseases of aging. These projects include the following:

  • Understanding the role of gut microbiome in contributing to HIV pathogenesis and mucosal and systemic inflammation
  • Understanding the impact of inflammatory responses on the innate immune system in both systemic and mucosal sites
  • Understanding the role of inflammation and the microbiome on serious non-AIDS events, including neurocognitive, cardiovascular, metabolic and bone disease in HIV-infected individuals
  • Understanding factors that affect adaptive and innate immune reconstitution in the gastrointestinal tract of HIV-infected individuals
  • Understanding immunological factors that contribute to poor vaccine and immunologic responses in older individuals

Alan Landay, PhD, directs the Rush Immunology Specialty Laboratory (ISL), which performs immunologic assays for AIDS Clinical Trials Group (ACTG). The Rush ISL supports new ACTG trials, with a special focus on end-organ disease/inflammation. This includes both phenotypic and functional characterization of innate and adaptive immune cells such as innate lymphoid cells (ILCs), monocytes, natural killer (NK) cells, T and B cells.

Technology

Multi-color flow cytometry, enzyme-linked immunosorbent assay (ELISA)

Funding

The lab is currently funded by NIH RO1, R24, U01 and P20 grants from NIH

Our team

Contact us